Oncoloxía médica
Servizo
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (137)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
-
Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology
Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 98-108
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology
-
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
2023
-
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)
Scientific Reports
-
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Thrombosis Research, Vol. 232, pp. 133-137
-
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Expert Review of Anticancer Therapy, Vol. 23, Núm. 1, pp. 95-106
-
MET alterations in NSCLC—Current Perspectives and Future Challenges
Journal of Thoracic Oncology, Vol. 18, Núm. 4, pp. 419-435
-
Noninvasive detection of microsatellite instability in patients with endometrial cancer
International Journal of Cancer, Vol. 152, Núm. 10, pp. 2206-2217
-
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476
-
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Annals of Oncology, Vol. 34, Núm. 10, pp. 920-933
-
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
Cancer Treatment and Research Communications, Vol. 37
-
SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2627-2633
-
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
Cancers, Vol. 15, Núm. 11
2022
-
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
-
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Clinical Lung Cancer, Vol. 23, Núm. 8, pp. 720-730